Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

About this update from Outlook Therapeutics, Inc.

[{"type":"image","alt":"Outlook Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Outlook Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qNsjgbA2tq9jniYix8cXEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"ONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":201,"olType":false},{"type":"text","content":"ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update.","length":322,"tagName":"p"},{"type":"text","content":"Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $20.2 million, or $0.55 per basic and diluted share, and $1.5 million of revenue. Revenue consisted of the initial sales into Germany and the UK for LYTENAVA™ where title to the product has transferred to the distributor. This compares with net loss attributable to common stockholders of $0.89 per basic and diluted share for the same period last year, and no revenue.","length":568,"tagName":"p"},{"type":"text","content":"For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics also reported an adjusted net loss attributable to common stockholders of $15.8 million, or $0.44 per basic and diluted share, as compared to an adjusted net loss attributable to common stockholders of $19.2 million, or $0.83 per basic and diluted share, for fiscal third quarter 2024.","length":356,"tagName":"p"},{"type":"text","conte...

More updates from Outlook Therapeutics, Inc.